What is the recovery time after stem cell therapy for Hip Osteoarthritis?
Recovery and risk depend on the exact product, image-guided route and patient factors, so universal same-day, walking or return-to-activity timelines are unsafe. Trial documents should describe activity restrictions, infection and adverse-event monitoring, emergency arrangements and rehabilitation. Functional progression should be based on clinical assessment, not presumed cell integration.
What the evidence shows for Hip Osteoarthritis
Human hip-OA studies of cell and related biological products vary by disease severity, product, dose, comparator, imaging method, rehabilitation and endpoint. Pain or function changes do not establish cartilage repair, and uncontrolled imaging changes cannot prove slower progression or avoidance of joint replacement. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Am I a candidate? → · Hip Osteoarthritis: full overview → · Hip Osteoarthritis cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.